NASDAQ: FBIO - Fortress Biotech, Inc.

Rentabilité sur six mois: +41.32%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions Fortress Biotech, Inc.


À propos de l'entreprise Fortress Biotech, Inc.

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne.

plus de détails
It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

IPO date 2011-11-17
ISIN US34960Q1094
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.fortressbiotech.com
Цена ао 1.93
Changement de prix par jour: +14.56% (2.06)
Changement de prix par semaine: +37.21% (1.72)
Changement de prix par mois: +28.96% (1.83)
Changement de prix sur 3 mois: +58.39% (1.49)
Changement de prix sur six mois: +41.32% (1.67)
Changement de prix par an: -21.59% (3.01)
Evolution du prix sur 3 ans: +804.21% (0.261)
Evolution du prix sur 5 ans: +1 104.08% (0.196)
Evolution des prix sur 10 ans: 0% (2.36)
Evolution des prix depuis le début de l'année: +28.26% (1.84)

Sous-estimation

Nom Signification Grade
P/S 0.2639 10
P/BV 14.05 1
P/E 0 0
EV/EBITDA -0.2285 0
Total: 5.13

Efficacité

Nom Signification Grade
ROA, % -36.2 0
ROE, % -268.97 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.536 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 130.91 10
Rentabilité Ebitda, % 29 4
Rentabilité EPS, % 689.52 10
Total: 6.4

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
iShares Micro-Cap ETF 0.00549 17.09 1.54048



Superviseur Titre d'emploi Paiement Année de naissance
Dr. Lindsay Allan Rosenwald Executive Chairman, President & CEO 212.66k 1955 (70 années)
Mr. Michael S. Weiss Esq. Executive Vice Chairman of Strategic Development & Director 182.66k 1966 (59 années)
Mr. David Jin CFO & Head of Corporate Development 407.33k 1990 (35 années)
Dr. George C. Avgerinos Senior Vice President of Biologics Operations 386.49k 1954 (71 année)
Mr. Samuel Berry General Counsel & Corporate Secretary N/A

Adresse: United States, Bay Harbor Islands. FL, 1111 Kane Concourse - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.fortressbiotech.com